摘要
目的:应用化学发光标记免疫法联合检测四项肿瘤标志物对肝脏疾病的癌变诊断价值。方法:以化学发光标记免疫法对肝癌组56例、肝硬化组40例、肝炎组47例及正常对照组30例的血清甲胎蛋白(AFP)、癌胚抗原(CEA)、CA199和铁蛋白(SF)进行联检。结果:肝癌组AFP、CEA、SF,肝硬化组AFP、SF相应指标与正常对照组相应指标比较,均具有非常显著性差异或显著性差异(P<0. 01或P<0. 05),但肝炎组无显著性差异(P>0 05)。同时血清CEA、CA199、SF联检对原发性肝癌与转移性肝癌有显著性差异。结论:应用多项指标联检对肝脏疾病的癌变(尤其是原发性肝癌)的检出率可达95%以上,同时对原发性肝癌与转移性肝癌有很好的鉴别作用。
Objective To investigate the diagnostic value of combined detection of four tumor markers in patients with possible malignant change in liver disorders. Methods Serum AFP,CEA,CA199 and SF levels were determined with chemiluminescence immunoassay (CLIA) in 49 patients with primary liver curcinoma, 7 patients with metastatic liver carcinoma, 40 patients with hepatic cirrhosis, 47 patients with HBV hepatitis and 30 controls. Results The serum levels of AFP,CEA,SF in patients with primary hepatic cancer and serum levels of AFP,SF in patients with hepatic cirrhosis were all significantly higher than those in controls (P<0.01 or 0.05). However, serum levels of the four markers in patients with hepatitis were not much different from those in controls (P>0.05). Moreover, positive rate of combined determination of AFP,CEA,CA199,SF in patients with primary hepatic cancer was significantly higher than that in patients with metastatic liver cancer. Conclusion With combined determination of these four tumor markers, the detection rate of primary hepatic carcinoma could be enhanced to above 95%. Also, differential diagnosis between primary and metastatic hepatic cancers could be facilitated.
出处
《放射免疫学杂志》
CAS
2005年第2期142-144,共3页
Journal of Radioimmanology
